I have reported a novel slot blot analysis to quantify two types of AGEs, glyceraldehyde-derived AGEs, also called toxic AGEs (TAGE), and 1,5-anhydro-D-fructose AGEs. or their respective owners, and all rights are reserved.Various types of advanced glycation end-products (AGEs) have been identified and studied. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.īioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. This product is supplied subject to the terms and conditions, including the limited license, located at ('Terms') and may be used only as provided in the Terms. (PubMed link indicates BioLegend citation) This antibody is effective in immunoblotting (WB). It is recommended that the reagent be titrated for optimal performance for each application. For Western blotting, the suggested use of this reagent is 0.5 - 1.0 µg/mL. For immunohistochemistry on formalin-fixed paraffin-embedded tissue sections, a concentration range of 5 - 10 µg/mL is suggested. You can also check your vial or your CoA to find the most accurate storage condition for this antibody.Įach lot of this antibody is quality control tested by Western blotting. Please note the storage condition for this antibody has been changed from -20☌ to between 2☌ and 8☌. The antibody solution should be stored undiluted between 2☌ and 8☌. The antibody was purified by affinity chromatography. Phosphate-buffered solution (no preservatives or carrier proteins). This antibody was raised against a peptide sequence corresponding to aa 141-160 of human Apo-E. Enhanced chemiluminescence was used as the detection system. The blot was incubated with 1 µg/mL of the primary antibody overnight at 4☌, followed by incubation with HRP labeled goat anti-mouse IgG (Cat. Lane 1: Molecular weight marker Lane 2: 40 ng of Apo E2 recombinant protein Lane 3: 40 ng of Apo E3 recombinant protein Lane 4: 40 ng of Apo E4 recombinant protein Lane 5: 40 µg of human plasma. Western blot of purified anti-Apo E antibody (clone D6E10). The image was captured with a 40X objective. 405322) for one hour at room temperature. Following antigen retrieval using Sodium Citrate H.I.E.R., the tissue was incubated with 10 µg/mL of the primary antibody overnight at 4☌, followed by incubation with Alexa Fluor® 647 goat anti-mouse IgG (Cat No. IHC staining of purified anti-Apo E antibody (clone D6E10) antibody on formalin-fixed paraffin-embedded Alzheimer’s disease brain tissue.

929901) was used for detection followed by hematoxylin counterstaining, according to the protocol provided. BioLegend's Ultra Streptavidin (USA) HRP Detection Kit (Multi-Species, DAB, Cat. Following antigen retrieval using Sodium Citrate H.I.E.R., the tissue was incubated with 10 µg/mL of the primary antibody overnight at 4☌. IHC staining of purified anti-Apo E antibody (clone D6E10) on formalin-fixed paraffin-embedded human cerebellum tissue. Following antigen retrieval using Sodium Citrate H.I.E.R., the tissue was incubated with 5 µg/mL of the primary antibody overnight at 4☌. IHC staining of purified anti-Apo E antibody (clone D6E10) on formalin-fixed paraffin-embedded Alzheimer’s disease brain tissue.

Peptide dot blot protocol